Praveen Tyle
Independent Chairman of the BoardDr. Praveen Tyle, Ph.D. serves as Director at Gila Therapeutics, Inc. He serves as an Independent Chairman of the Board at Kiora Pharmaceuticals, Inc. since September 20, 2023. He serves as CEO & Director of Orion Biotechnology Canada, Ltd. He served as Director at Maxwell Biosciences, Inc. until 2024. He serves as Member of Advisory Board at Yolia Health. Dr. Tyle served as Independent Director at Skye Bioscience, Inc. since July 2021 until August 01, 2024. He had been Executive Vice President of Research and Development at Lexicon Pharmaceuticals, Inc. since May 16, 2016 until April 26, 2021. Dr. Tyle served as an Independent Non-Executive Director at GI Dynamics, Inc. since February 2020 until August 10, 2020. Dr. Tyle serves as Member of Executive Board at Rapid Pharmaceuticals AG. Dr. Tyle brings experience in the pharmaceutical industry, with senior executive leadership positions encompassing research and development, clinical development, manufacturing, regulatory, business development and operations as well as roles as a board director and scientific advisory board member. Dr. Tyle joined Lexicon with pharmaceutical industry experience of advancing new medical device and drug candidate pipelines to commercial success. He led and completed the successful merger of Vertical Pharmaceuticals and Trigen Laboratories with Osmotica Holdings in February 2016. He served as the Chief Executive Officer and President of Osmotica Pharmaceutical Corp. since January 2013 until April 2016. He served as the Chief Scientific Officer and Executive Vice President of Osmotica Pharmaceutical Corp. from August 2012 to December 2012. He served as President and Chief Executive Officer of Osmotica Holdings. He served as Senior Advisor at Arsenal Capital Partners, Inc. Prior to joining Osmotica Pharmaceutical Corp. Dr. Tyle served as Executive Vice President (from January 2012 to August 2012) and Chief Scientific Officer (from October 2011 to August 2012) for the United States Pharmacopeia. Dr. Tyle served as the Chief Scientific Officer and Corporate Senior Vice President of Research & Development of Bausch & Lomb Incorporated since July 19, 2004. Dr. Tyle focused in areas including vision care (lens and lens care), pharmaceuticals (prescription, OTC, generics, nutritionals) and surgical (refractive and cataract). He is also responsible for all of Bausch & Lomb's preclinical development programs, product development efforts and clinical, medical and regulatory affairs and quality assurance. Dr. Tyle joined Bausch & Lomb from Valeant Pharmaceuticals International, Inc. (also known as Biovail Corporation), where he served as Group Vice President of Pharmaceutical Sciences and Manufacturing since June 5, 2003. Dr. Tyle has experience in the pharmaceutical industry with the majority of his tenure in senior executive leadership positions in areas of research and development, manufacturing, quality, business development and operations. He worked nearly four years at Pharmacia Corporation, where he served as Vice President and Global Head of Pharmaceutical Sciences. Prior to joining USP, Dr. Tyle from 2008 to 2011, served as the Senior Vice President and Global Head of Business Development and Licensing at Novartis Consumer Health from March 2009 to September 2011 as well as Senior Vice President & Global Head of Research and Development. Dr. Tyle began his professional career as a formulations research chemist in drug delivery research with American Cynamid Company (now Wyeth), moving on to executive leadership and scientific positions with Sandoz Pharmaceuticals (now Novartis), Agouron Pharmaceuticals (now Pfizer) and Aronex Pharmaceuticals (now Antigenics). Since 1999, he served as Vice President of Pharmaceutical sciences at U.S. Pharmacia & Upjohn (now Pfizer). Dr. Tyle has been an Independent Director of Kiora Pharmaceuticals, Inc. (formerly known as EyeGate Pharmaceuticals, Inc.) since June 2008. He serves as an Independent Director of Interpath Pharmaceuticals, Houston. He was an Independent Director of Orient Europharma Co. Ltd. until June 18, 2025. He serves as Director of GrayBug, LLC and Yolia Health. Dr. Tyle has been a Member of Scientific Advisory Board at Vioquest Pharmaceuticals Inc. since August 1, 2006. He serves as Member of the Council of Healthcare Advisors, the advisory Board of Oakland University Center for Biomedical Research and is a Scientific Advisor to CB Health Ventures of Boston and Epimmune Inc. of San Diego. He served as a Member of Scientific Advisory Board of Vela Pharmaceuticals Inc. He served as a Board Member of Osmotica Holdings. He served as a Director of Osmotica Pharmaceutical Corp. since January 2013 until 2016. Dr. Tyle serves as adjunct professor at Howard University and the University of Rochester Medical Center. He holds academician appointments as an Adjunct Professor of Pharmacy at the University of Rhode Island and at the University of Houston, Texas. Dr. Tyle is Editor of seven books about drug development, holds several patents and is author of more than 130 technical and scientific papers and presentations. He received the Distinguished Alumni award from the Institute of Technology, Banaras Hindu University. Dr. Tyle has been honored as a distinguished research fellow by the Shandong Pharmaceutical Research Institute, China. Dr. Tyle is President & Chief Executive Officer and a director of Invectys, Inc since April 2021, an immuno-oncology company spun out of the world-renowned Pasteur Institute. Dr. Tyle received a Ph.D. degree in Pharmaceutics and Pharmaceutical Chemistry from the Ohio State University in 1984 and a Bachelor of Pharmacy degree the Indian Institute of Technology, Banaras Hindu University in India in 1980. Dr. Tyle was also an Adjunct Associate Professor of Ophthalmology at the University of Rochester Eye Institute Medical Center, among other current and past academic roles. He has co-authored over 100 peer-reviewed academic papers and presentations and is named on multiple patents, including patents related to ophthalmic innovations, drug delivery and glaucoma.
Positions
- Company NameKiora Pharmaceuticals, Inc.Stock CodeKPRXPositionIndependent Chairman of the BoardColleagues
- BMBrian M. StremPresident, CEO & Director
- MTMelissa ToscaChief Financial Officer
- SSStefan SperlExecutive Vice President of CMC & Operations
- KJKeith J. LaneExecutive VP and Head of Clinical Development & Regulatory Affairs
- DADavid A. HollanderIndependent Director
- EPErin ParsonsNon-Employee Independent Director
- LWLisa Walters-HoffertIndependent Director
